Translational Research Institute
The new $354 million Translational Research Institute (TRI) will bring together four of Australia’s pinnacle research facilities with the aim of improving and accelerating medical research and translating that research into greater patient care. The TRI will allow, for the first time in Australia, biopharmaceuticals and treatments to be discovered, produced, clinically tested, and manufactured in one location.
The TRI is a joint venture between The University of Queensland Diamantina Institute, Queensland University of Technology's Biomedical Innovation, Mater Medical Research Institute, and the Princess Alexandra Hospital's Centres for Health Research.
The centre was the vision of world-renowned inventor of the cervical cancer vaccine and 2006 Australian of the Year, Professor Ian Frazer, and the Mater Medical Research Institute.
To discover more information, please click here to visit the Translational Research Institute website, or contact the Investment Attraction Team.